Earnings Estimates Moving Higher for Amicus Therapeutics ( FOLD ) : Time to Buy?
Amicus Therapeutics (FOLD) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
Does Amicus Therapeutics ( FOLD ) Have the Potential to Rally 138.21% as Wall Street Analysts Expect?
The average of price targets set by Wall Street analysts indicates a potential upside of 138.2% in Amicus Therapeutics (FOLD). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Amicus ( FOLD ) Q2 Revenue Jumps 22%
Amicus Therapeutics ( NASDAQ:FOLD ) , a specialist in rare disease medicines, delivered quarterly results on July 31, 2025 that notably surpassed expectations on both GAAP revenue and non-GAAP earnings. The company reported GAAP revenue of $154.7 million, up from $126.7 million ( GAAP ) a year ...
FOLD Q2 Earnings Miss Mark, Revenues Beat on Higher Product Sales
Amicus misses second-quarter earnings estimates but beats the same for revenues, driven by strong sales of Galafold and Pombiliti + Opfolda.
Amicus Therapeutics ( FOLD ) Misses Q2 Earnings Estimates
Amicus Therapeutics (FOLD) delivered earnings and revenue surprises of -50.00% and +4.87%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Amicus Therapeutics Announces Second Quarter 2025 Financial Results and Corporate Updates
Q2 2025 Total Revenue of $154.7M, up 18% at ...
Moderna ( MRNA ) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
Moderna (MRNA) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Analysts Estimate Amicus Therapeutics ( FOLD ) to Report a Decline in Earnings: What to Look Out for
Amicus Therapeutics (FOLD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Amicus Therapeutics Announces Approval of Pombiliti® ( cipaglucosidase alfa ) + Opfolda® ( miglustat ) in Japan - Amicus Therapeutics ( NASDAQ:FOLD )
PRINCETON, N.J., and TOKYO, June 25, 2025 ( GLOBE NEWSWIRE ) -- Amicus Therapeutics FOLD today announced that Japan's Ministry of Health, Labour and Welfare ( MHLW ) has approved Pombiliti ( cipaglucosidase alfa ) + Opfolda ( miglustat ) for the treatment of adult patients with late-onset Pompe ...
New Strong Sell Stocks for June 3rd
FOLD, BRCC and VLVLY have been added to the Zacks Rank #5 (Strong Sell) List on May 3, 2025.
New Analysis of Pombiliti® ( cipaglucosidase alfa-atga ) + Opfolda® ( miglustat ) Published in Muscle and Nerve
PRINCETON, N.J., June 03, 2025 ( GLOBE NEWSWIRE ) -- Amicus Therapeutics ( Nasdaq: FOLD ) , today announced the publication of a post-hoc analysis of data from the ERT-experienced cohort of the PROPEL study of cipaglucosidase alfa-atga + miglustat ( cipa+mig ) in adults with late-onset Pompe ...
Amicus Therapeutics to Present at Upcoming Investor Conferences in June 2025 - Amicus Therapeutics ( NASDAQ:FOLD )
PRINCETON, N.J., May 30, 2025 ( GLOBE NEWSWIRE ) -- Amicus Therapeutics FOLD today announced that management will participate in upcoming presentations at the following investor conferences in June. Jefferies Global Healthcare Conference 2025 in New York, NY, on Wednesday, June 4, 2025, at ...
Amicus Therapeutics to Present at Upcoming Investor Conferences in June 2025
PRINCETON, N.J., May 30, 2025 ( GLOBE NEWSWIRE ) -- Amicus Therapeutics ( Nasdaq: FOLD ) today announced that management will participate in upcoming presentations at the following investor conferences in June.
FOLD Q1 Earnings and Sales Miss Estimates, Stock Falls
Amicus' first-quarter 2025 earnings and sales miss estimates. Shares decline.
Bausch Health Q1 Earnings and Revenues Miss Estimates, Stock Down
BHCs first-quarter 2025 adjusted earnings and revenues miss estimates. Salix performs lower than expected. Stock declines.
Amicus Therapeutics ( FOLD ) Q1 Earnings and Revenues Lag Estimates
Amicus Therapeutics (FOLD) delivered earnings and revenue surprises of -62.50% and 7.66%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Dimerix and Amicus Therapeutics Announce Exclusive License Agreement for DMX-200 in the United States
Amicus licenses exclusive U.S. rights to commercialize DMX-200 for the treatmentof Focal Segmental ...
Earnings Preview: Y-mAbs Therapeutics, Inc. ( YMAB ) Q1 Earnings Expected to Decline
YmAbs Therapeutics (YMAB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Amicus Therapeutics ( FOLD ) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
Amicus Therapeutics (FOLD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Amicus Therapeutics to Report Q1 Earnings: What's in the Cards?
On FOLD's first-quarter 2025 earnings call, investors are likely to focus on the sales of lead drug Galafold and the combo drug, Pombiliti + Opfolda.
Amicus Therapeutics to Announce First Quarter 2025 Financial Results on May 1, 2025
PRINCETON, N.J., April 21, 2025 ( GLOBE NEWSWIRE ) -- Amicus Therapeutics ( Nasdaq: FOLD ) today announced that the Company will host a conference call and live audio webcast on Thursday, May 1, 2025, at 8:30 a.m. ET to discuss financial results for the first quarter ended March 31, 2025.
Apellis Announces Craig Wheeler to Join the Board of Directors
WALTHAM, Mass., April 21, 2025 ( GLOBE NEWSWIRE ) -- Apellis Pharmaceuticals, Inc. ( Nasdaq: APLS ) today announced that Craig Wheeler, founder and chief executive officer of Headwaters Biotech Advisors, will join the Apellis Board of Directors, effective immediately.
4 Healthcare Stocks to Buy as the Sector Faces Government Heat
Buy healthcare stocks like WGS, THC, RIGL and ENSG for steady returns as the focus shifts to the Trump administration's healthcare policies.
BMY Down on Heart Drug Camzyos Failure in Late-Stage Study
Bristol Myers phase III study evaluating Camzyos for the treatment of adult patients with non-obstructive hypertrophic cardiomyopathy fails to meet its dual-primary endpoints.
Bayer Obtains Full FDA Approval for Oncology Drug Vitrakvi
The FDA converts its accelerated approval to full approval for BAYRY's oncology drug, Vitrakvi, on positive data from confirmatory studies.
BMY Gets FDA Nod for Label Expansion of Opdivo plus Yervoy Combo
Bristol Myers gets FDA approval for Opdivo monotherapy and Opdivo plus Yervoy combination for colorectal cancer in the first-line setting.
RLYB Ends Pregnancy-Related Rare Disease Program, Stock Tanks
Rallybio halts development of RLYB212 in a phase II study for the prevention of fetal and neonatal alloimmune thrombocytopenia. Stock falls.
5 Biotech Stocks Worth Adding Amid Global Uncertainty in 2025
New drug approvals and encouraging pipeline progress should maintain momentum in the Zacks Biomedical and Genetics industry despite the uncertain macroeconomic environment. A strong portfolio and solid pipeline progress position GILD, BMRN, KRYS, ADMA and FOLD well in this volatile sector.
GRI Stock Down on Public Offering Despite Encouraging IPF Study Data
GRI stock plunges on the pricing of its public offering, paring the gains witnessed following positive IPF study results.
CHMP Issues Positive Opinion for Label Expansion of BMY's Opdivo
BMY obtains CHMP recommendation for Opdivo for perioperative regimen of neoadjuvant Opdivo and chemotherapy followed by surgery and adjuvant Opdivo for resectable non-small cell lung cancer.
CORT Shares Rise as Relacorilant Combo Meets Ovarian Cancer Study Goal
The ROSELLA study evaluating Corcept's relacorilant plus nab-paclitaxel for treating patients with platinum-resistant ovarian cancer meets the primary endpoint.
New Strong Buy Stocks for April 1st
AFRM, TKOMY, FOLD, MASS and VFC have been added to the Zacks Rank #1 (Strong Buy) List on April 1, 2025.
Amicus Therapeutics ( FOLD ) Up 0.1% Since Last Earnings Report: Can It Continue?
Amicus Therapeutics (FOLD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Acadia's Q4 Earnings Miss, Nuplazid & Daybue Drive Revenue Growth ( Revised )
ACAD reports mixed fourth-quarter results as earnings missed estimates while revenues beat the same, driven by year-over-year growth in Nuplazid and Daybue sales.
KRYS Gets Positive CHMP Opinion for EU Approval of Skin Disease Drug
Krystal Biotech receives positive CHMP opinion recommending the approval of Vyjuvek for treating dystrophic epidermolysis bullosa in the EU.
Apellis Q4 Loss Narrower Than Expected, Syfovre Sales Drive Revenues
APLS reports better-than-expected fourth-quarter 2024 results, wherein both earnings and revenues beat estimates, driven by strong sales of Syfovre.
Pacira Q4 Earnings Top, Revenues Miss Despite Exparel Sales Growth
PCRX reports mixed fourth-quarter 2024 results, wherein earnings beat estimates but revenues miss. Exparel sales witness year-over-year growth.
PBYI Stock Rises as Q4 Earnings & Sales Outpace Estimates
Puma Biotechnology beats on fourth-quarter 2024 earnings and sales. The company issues a fresh financial guidance for 2025.
Viatris Q4 Earnings and Revenues Miss Estimates, Stock Plunges
VTRS Q4 earnings and sales miss estimates. The guidance for 2025 looks disappointing due to the financial impact of the Indore facility warning letter and import alert. Stock down.
Acadia's Q4 Earnings Miss, Nuplazid & Daybue Drive Revenue Growth
ACAD reports mixed fourth-quarter results as earnings missed estimates while revenues beat the same, driven by year-over-year growth in Nuplazid and Daybue sales.
CPRX Q4 Earnings Beat, Firdapse Sales Boost Revenues, Stock Up
Catalyst stock gains on strong fourth-quarter results, beating earnings and revenue estimates, primarily driven by Firdapse sales.
Amicus Therapeutics to Present at Upcoming Investor Conferences in March 2025 - Amicus Therapeutics ( NASDAQ:FOLD )
PRINCETON, N.J., Feb. 27, 2025 ( GLOBE NEWSWIRE ) -- Amicus Therapeutics FOLD today announced that management will participate in upcoming presentations at the following investor conferences in March. TD Cowen 45th Annual Health Care Conference in Boston, MA, on Tuesday, March 4, 2025, at ...
Madrigal Q4 Earnings Beat, MASH Drug Sales Drive Top Line, Stock Up
MDGL stock is rising as it reports better-than-expected fourth-quarter results, beating earnings and revenue estimates, driven by strong Rezdiffra sales.
United Therapeutics Stock Down Despite Q4 Earnings & Sales Beat
UTHR beats fourth-quarter estimates for both earnings and sales. Tyvaso sales fall short of estimates. Stock down in pre-market trading.
ITCI Q4 Loss Wider Than Expected, Revenues Top on Higher Caplyta Sales
Intra-Cellular reports mixed fourth-quarter 2024 results, wherein earnings miss estimates but revenues beat the same driven by strong Caplyta sales.
FOLD's Q4 Earnings Miss, Higher Product Sales Drive Revenue Growth
Amicus' fourth-quarter 2024 earnings miss estimates while revenues beat the same.
Krystal Biotech Q4 Earnings Beat Estimates, Sales Miss, Stock Up
KRYS stock gains despite reporting mixed fourth-quarter results as lead drug Vyjuvek's launch in the United States shows strong uptake.
Amicus Therapeutics ( FOLD ) Q4 Earnings and Revenues Miss Estimates
Amicus Therapeutics (FOLD) delivered earnings and revenue surprises of -10% and 0.13%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
Amicus Therapeutics Announces Full-Year 2024 Financial Results and Corporate Updates
2024 Total Revenue of $528.3M, a 33% Increase ...
Kuehn Law Encourages Investors of Amicus Therapeutics, Inc. to Contact Law Firm - Amicus Therapeutics ( NASDAQ:FOLD )
NEW YORK, Feb. 17, 2025 ( GLOBE NEWSWIRE ) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Amicus Therapeutics, Inc. FOLD breached their fiduciary duties to shareholders. The investigation concerns potential self-dealing.
